+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Monoclonal Antibodies Market Research Report by Source Type (Chimeric, Human, and Humanized), Production Type, Indication, End-User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5311207
  • Report
  • April 2022
  • Region: Global
  • 181 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbott Laboratories
  • ADC Therapeutics
  • Astellas Pharma Inc
  • Biogen Idec Inc.
  • F. Hoffmann-La Roche AG
  • Mylan N.V.
The Global Monoclonal Antibodies Market size was estimated at USD 100.30 billion in 2021, USD 112.47 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.30% to reach USD 201.29 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Source Type, the market was studied across Chimeric, Human, Humanized, and Murine.
  • Based on Production Type, the market was studied across In Vitro and In Vivo.
  • Based on Indication, the market was studied across Autoimmune Diseases, Cancer, Infectious Diseases, Inflammatory Diseases, and Microbial Diseases.
  • Based on End-User, the market was studied across Hospitals and Research Institutes.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Monoclonal Antibodies market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Monoclonal Antibodies Market, including Abbott Laboratories, AbbVie, Inc, AbGenomics, ADC Therapeutics, ALMAC Group, Amgen Inc., Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Biogen Idec Inc., Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Seagen Inc., Shanghai Junshi Biosciences Co., Ltd., and Thermo Fisher Scientific, Inc.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Monoclonal Antibodies Market?
6. What is the market share of the leading vendors in the Global Monoclonal Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Monoclonal Antibodies Market?
Frequently Asked Questions about the Global Monoclonal Antibodies Market

What is the estimated value of the Global Monoclonal Antibodies Market?

The Global Monoclonal Antibodies Market was estimated to be valued at $100.3 Billion in 2021.

What is the growth rate of the Global Monoclonal Antibodies Market?

The growth rate of the Global Monoclonal Antibodies Market is 12.3%, with an estimated value of $201.3 Billion by 2027.

What is the forecasted size of the Global Monoclonal Antibodies Market?

The Global Monoclonal Antibodies Market is estimated to be worth $201.3 Billion by 2027.

Who are the key companies in the Global Monoclonal Antibodies Market?

Key companies in the Global Monoclonal Antibodies Market include Abbott Laboratories, AbbVie, Inc, AbGenomics, ADC Therapeutics, ALMAC Group, Amgen Inc., Astellas Pharma Inc, AstraZeneca PLC and Biogen Idec Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • ADC Therapeutics
  • Astellas Pharma Inc
  • Biogen Idec Inc.
  • F. Hoffmann-La Roche AG
  • Mylan N.V.

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
5.1.2. Restraints
5.1.2.1. Pricing of therapeutic mAbs are expensive
5.1.3. Opportunities
5.1.3.1. High adoption rate in developing countries
5.1.3.2. Substantial increase in the number of approvals per year
5.1.4. Challenges
5.1.4.1. Limitation in current manufacturing and purification processes (risk of contamination) affect production capacity and led to increasing cost
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Monoclonal Antibodies Market, by Source Type
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
6.5. Murine
7. Monoclonal Antibodies Market, by Production Type
7.1. Introduction
7.2. In Vitro
7.3. In Vivo
8. Monoclonal Antibodies Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Infectious Diseases
8.5. Inflammatory Diseases
8.6. Microbial Diseases
9. Monoclonal Antibodies Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
10. Americas Monoclonal Antibodies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Monoclonal Antibodies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Monoclonal Antibodies Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.2. AbbVie, Inc
14.3. AbGenomics
14.4. ADC Therapeutics
14.5. ALMAC Group
14.6. Amgen Inc.
14.7. Astellas Pharma Inc
14.8. AstraZeneca PLC
14.9. Bayer AG
14.10. Biogen Idec Inc.
14.11. Bristol Myers Squibb
14.12. Daiichi Sankyo Company, Limited
14.13. Eli Lilly and Company
14.14. F. Hoffmann-La Roche AG
14.15. GenScript Biotech Corporation
14.16. GlaxoSmithKline PLC
14.17. Johnson & Johnson Services, Inc.
14.18. Merck & Co., Inc.
14.19. Mylan N.V.
14.20. Novartis International AG
14.21. Novo Nordisk A/S
14.22. Pfizer Inc
14.23. Sanofi S.A.
14.24. Seagen Inc.
14.25. Shanghai Junshi Biosciences Co., Ltd.
14.26. Thermo Fisher Scientific, Inc
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL MONOCLONAL ANTIBODIES MARKET: DYNAMICS
FIGURE 2. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2027
FIGURE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2021 VS 2027 (%)
FIGURE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2027
FIGURE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD BILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2027
FIGURE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, 2019-2027 (USD BILLION)
FIGURE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, 2019-2027 (USD BILLION)
FIGURE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, 2019-2027 (USD BILLION)
FIGURE 30. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2021 VS 2027 (USD BILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2027
FIGURE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, 2019-2027 (USD BILLION)
FIGURE 37. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 38. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, 2019-2027 (USD BILLION)
FIGURE 39. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 40. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 66. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 67. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 68. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. GLOBAL MONOCLONAL ANTIBODIES MARKET: FPNV POSITIONING MATRIX
FIGURE 71. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 72. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MONOCLONAL ANTIBODIES MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL MONOCLONAL ANTIBODIES MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 42. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 44. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 47. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 49. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 52. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 54. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 57. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 59. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2019-2027 (USD BILLION)
TABLE 62. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD BILLION)
TABLE 63. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 64. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD BILLION)
TABLE 65. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 67. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2019-2027 (USD BILLION)
TABLE 68. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 69. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY STATE, 2019-2027 (USD BILLION)
TABLE 70. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 72. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. AUSTRALIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 86. SINGAPORE MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. TAIWAN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 92. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 93. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 94. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 95. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 96. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 97. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 98. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 99. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 100. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 101. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 102. GLOBAL MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 103. GLOBAL MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 104. GLOBAL MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 105. GLOBAL MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 106. GLOBAL MONOCLONAL ANTIBODIES MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 107. GLOBAL MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 108. GLOBAL MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 109. GLOBAL MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 110. GLOBAL MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 111. GLOBAL MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 112. GLOBAL MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • AbbVie, Inc
  • AbGenomics
  • ADC Therapeutics
  • ALMAC Group
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Idec Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GenScript Biotech Corporation
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi S.A.
  • Seagen Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Thermo Fisher Scientific, Inc
Note: Product cover images may vary from those shown

Loading
LOADING...